312 related articles for article (PubMed ID: 28795280)
21. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
22. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
[TBL] [Abstract][Full Text] [Related]
25. Optimization of b-values in diffusion-weighted imaging for esophageal cancer: Measuring the longitudinal length of gross tumor volume and evaluating chemoradiotherapeutic efficacy.
Liu G; Yang Z; Li T; Yang L; Zheng X; Cai L
J Cancer Res Ther; 2017; 13(5):748-755. PubMed ID: 29237898
[TBL] [Abstract][Full Text] [Related]
26. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
[TBL] [Abstract][Full Text] [Related]
28. Multimodality Treatment and Prognosis in Esophageal Squamous Cell Carcinoma Requiring Esophagectomy.
Yamashita K; Katada N; Moriya H; Hosoda K; Sakuramoto S; Kikuchi S; Watanabe M
Hepatogastroenterology; 2014 Jun; 61(132):1042-8. PubMed ID: 26158163
[TBL] [Abstract][Full Text] [Related]
29. Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
Fujiwara Y; Lee S; Kishida S; Hashiba R; Gyobu K; Naka R; Nishiyama M; Ihara T; Takemura M; Osugi H
Int J Clin Oncol; 2018 Oct; 23(5):877-885. PubMed ID: 29752605
[TBL] [Abstract][Full Text] [Related]
30. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
[TBL] [Abstract][Full Text] [Related]
31. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.
Yamaguchi T; Kato K; Nagashima K; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Ito Y; Itami J; Boku N; Higuchi K
Int J Clin Oncol; 2018 Aug; 23(4):652-658. PubMed ID: 29520523
[TBL] [Abstract][Full Text] [Related]
32. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
Zhan M; Zheng H; Yang Y; Xu T; Li Q
Radiother Oncol; 2019 Dec; 141():27-32. PubMed ID: 31431378
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
36. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
37. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma.
Huang Y; Wang H; Luo G; Zhang Y; Wang L; Li K
Int J Surg; 2017 Feb; 38():41-47. PubMed ID: 28027995
[TBL] [Abstract][Full Text] [Related]
39. [IMRT-based preoperative neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma (ESCC): an analysis of outcome and prognosis].
Men Y; Hui ZG; Liang J; Feng QF; Chen DF; Zhang HX; Xiao ZF; Zhou ZM; Wang LH
Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):682-6. PubMed ID: 27647401
[TBL] [Abstract][Full Text] [Related]
40. EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
Anvari K; Sima HR; Seilanian Toussi M; Anvari A; Shahidsales S; Memar B; Aledavoud SA; Forghani MN; Abdollahi A; Ghaffarzadegan K
Arch Iran Med; 2017 Apr; 20(4):240-245. PubMed ID: 28412829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
